Health Care·Pharmaceuticals·$49.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.48 | N/A | +6.02% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.48 | N/A | +6.02% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed confidence in their product pipeline and market position. However, they acknowledged some ongoing challenges that could impact performance.
Management highlighted ongoing demand for animal health products.
They noted challenges in the supply chain but remain focused on innovation.
The team emphasized their commitment to long-term growth despite current market conditions.
Zoetis Inc reported a better-than-expected EPS for the quarter, which indicates strong profitability. However, the stock dropped by 5.18% likely due to the lack of revenue details and no guidance for the future. Investors may be concerned about the challenges mentioned by management, which could affect future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PALANTIR TECHNOLOGIE Class A
May 5, 2025